Takeda Inks $5.2B Deal For Oncology-Focused ARIAD
Takeda will buy hedge fund-backed ARIAD Pharmaceuticals in a $5.2 billion deal that stands to expand the Japanese pharma company's global oncology portfolio into solid tumors, as well as strengthen its...To view the full article, register now.
Already a subscriber? Click here to view full article